Ionis Pharmaceuticals (IONS) Income from Non-Controlling Interests (2009 - 2020)
Ionis Pharmaceuticals' quarterly Income from Non-Controlling Interests came in at -$1.2 million in Q4 2020, down 105.91% year-on-year from $19.5 million in Q1 2020, and up 90.49% quarter-over-quarter from -$12.1 million in Q3 2020.
Ionis Pharmaceuticals has reported Income from Non-Controlling Interests for 5 years, with the latest figure at -$1.2 million in Q4 2020.
- For the quarter ending Q4 2020, Income from Non-Controlling Interests fell 105.91% year-over-year to -$1.2 million; the trailing twelve-month figure through Sep 2021 stood at -$1.2 million (up 92.19% YoY), and the FY2020 full-year result was -$35.5 million, down 489.21% from the prior year.
- Income from Non-Controlling Interests for Q4 2020 stood at -$1.2 million, up from -$12.1 million in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $19.5 million in Q4 2019, with the low at -$17.3 million in Q4 2018.
- Average Income from Non-Controlling Interests over 4 years is -$6.9 million, with a median of -$9.3 million recorded in 2018.
- Year-over-year, Income from Non-Controlling Interests surged 212.67% in 2019 and plunged 259.2% in 2020.
- Tracing IONS's Income from Non-Controlling Interests over 4 years: stood at -$6.2 million in 2017, then plunged by 177.64% to -$17.3 million in 2018, then surged by 212.67% to $19.5 million in 2019, then slumped by 105.91% to -$1.2 million in 2020.
- The last three Income from Non-Controlling Interests figures came in at -$1.2 million (Q4 2020), -$12.1 million (Q3 2020), and -$11.9 million (Q2 2020), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.75 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Ionis Pharmaceuticals | 12.61 Bn | 10.69 Bn | 243.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -1.16 Mn |
| Sep 30, 2020 | -12.15 Mn |
| Jun 30, 2020 | -11.92 Mn |
| Mar 31, 2020 | -10.25 Mn |
| Dec 31, 2019 | 19.54 Mn |
| Sep 30, 2019 | -7.73 Mn |
| Jun 30, 2019 | -9.14 Mn |
| Mar 31, 2019 | 6.44 Mn |
| Dec 31, 2018 | -17.34 Mn |
| Sep 30, 2018 | -15.81 Mn |
| Jun 30, 2018 | -16.22 Mn |
| Mar 31, 2018 | -9.39 Mn |
| Dec 31, 2017 | -6.25 Mn |
| Sep 30, 2017 | -4.88 Mn |
| Dec 31, 2009 | -1.49 Mn |
| Sep 30, 2009 | -1.14 Mn |
| Jun 30, 2009 | -857,000.00 |